Использование ингибиторовфосфодиэстеразы 5-го типа у мужчин с эректильной дисфункцией и симптомами нижних мочевых путей

1. NIH Consensus Conference: Impotence: NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.
2. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (6): 637–49.
3. Johannes CB, Araujo AB, Feldman HA et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163 (2): 460–3.
4. Burnett AL. Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: association and management. Cur Urol Rep 2005; 6: 470–5.
5. Irwin DE, Milsom I, Hunskaar S et al. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study, 04 October 2006. Eur Urol 2006; 50 (6): 1306–15.
6. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78.
7. Kirby RS, Roenhborn C, Boyle P et al. Prospective European doxazosin and combination therapy study investigators. Efficasy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urol 2003; 61: 119–26.
8. Abrams P, Artibani W, Cardozo L et al. Reviewing the ICS 2002 Terminology Report: The ongoing debate. Neurourol Urodyn 2006; 25: 293.
9. Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002; 3: 445–51.
10. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651–9.
11. Braun MN, Sommer F, Haupt G et al. Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical «aging-male» symptoms? Results of the «Cologne Male Survey». Eur Urol 2003; 44: 588–94.
12. Glina S, Santana AW, Azank F et al. Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. BJU Int 2006; 97: 763–5.
13. Li MK, Garsia LA, Rosen R. Lower urinary tract symptoms and sexual dysfunction in Asia: A survey of ageing men from five Asian countries. BJU Int 2005; 96: 1339–54.
14. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I et al. Prevalence and independent risk-factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–74.
15. Boyle P, Robertson C, Mazetta C et al. The association between lower urinary tract symptoms and erectile dysfunction in four centers: The UrEpic study. BJU Int 2003; 92: 719–25.
16. Aslan G, Cavus E, Karas H et al. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl 2006; 52: 155–62.
17. Elliot SP, Gulati M, Spitalny GM et al. Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urol 2004; 63: 1148–52.
18. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677–85.
19. Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urol 2004; 64: 772–6.
20. Hansen BL. Lower urinary tract symptoms (LUTS) and sexual dysfunction in both sexes. Eur Urol 2004; 46: 229–34.
21. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006; 3: 676–81.
22. Marionneau N, Perrin P, Тaieb C. Lower urinary tract symptoms are poorly correlated with erectile dysfunction. Prog Urol 2006; 16 (5): 572–7.
23. Ponholzer A, Temml C, Wehrberger C et al. The аssociation between LUTS and vascular risk factors in both sexes. Eur Urol 2006; 50: 581–6.
24. Leliefeld HH, Stoevelaar HJ, McDonnel J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int 2002; 89: 208–13.
25. Uckert S, Ku the A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484–90.
26. Filippi S, Morelli A, Sandner P et al. Characterization and functional role of an androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019–29.
27. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259–63.
28. Guh JH, Hwang TL, Ko FN et al. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998; 53: 467–74.
29. Andersson KE, Persson K. Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand J Nephrol 1995; 175 (Suppl.): 43–53.
30. Persson K, Igawa Y, Matiasson A et al. Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 1992; 107: 178–84.
31. Tinel H, Stelte-Ludwig B et al. Pre-clinical evidence for the use of PDE5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract in vivo and in vitro. BJU Int 2006; 98: 1259–63.
32. Rees RW, Ziessen T, Ralph DJ et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002; 14: 1–7.
33. Wang H, Eto M, Steer WD et al. RhoA-mediated Ca2+ sensitization in erectile function. J Biol Chem 2002; 277: 306–14.
34. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522 (Pt 2): 177.
35. Wingard CJ, Husain S, Williams J, James S. RhoA-Rho-kinase mediates synergistic ET-1 and phenylephrine contraction of the rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2003; 285: 1145–52.
36. Chang S, Hypolite JA, Zderic SA et al. Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction. J Urol 2002; 167: 2636–44.
37. Bing W, Chang S, Hypolite JA et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 2003; 285: F990–7.
38. Rajasekaran M, White S, Baquir A, Wilkes N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 2005; 26: 182–8.
39. Гамидов С.И., Щербаков Д.В. Влияние метаболического синдрома на функциональное состояние эндотелия у больных органической эректильной дисфункцией. Андрол. и генит. хир. 2009; 2: 78.
40. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29–36.
41. Meigs JB, Mohr B, Barry MJ et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935–44.
42. McVary KT, Razzaq A, Lee C et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51: 99–107.
43. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174: 1327–433.
44. Holmquist F, Andersson KE, Hedlund H. Actions of endothelin on isolated corpus cavernosum from rabbit and man. Acta Physiol Scand 1990; 139: 113–22.
45. Azadzoi KM, Kim N, Brown ML et al. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 1992; 147: 220–5.
46. Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Wein PC, editor. Campbell's Urology. 8th ed. Philadelphia PA: Saunders; 2002; p. 187–90.
47. Uckert S, Sormes M, Kedia G et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526–30.
48. Tarcan T, Azadzoi KM, Siroky MB et al. Age related erectile and voiding dysfunction: the role of arterial insufficiency. Brit J of Urol 1998; 82: 26–33.
49. Sairam K, Kulinskaya E, McNicholas TA et al. Sildenafil improves lower urinary tract symptoms. BJU Int 2002; 90: 836–9.
50. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662–7.
51. McVary KT, Monnig W, Camps JL et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–7.
52. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomized placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236–44.
53. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
54. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–34.
55. Gacci M, Del Populo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178: 2040–3.
56. Klotz T, Mathers MJ, Bloch W et al. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999; 31: 335–41.
57. Mondul AM, Rimm EB, Giovannucci E et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol 2008; 179 (6): 2321–6.
58. Rajeev Kumar, Ajay Nehra, Debra J. Jacobson et al. a-Blocker use is associated with decreased risk of sexual dysfunction. Urol 2009; 74 (1): 82–7.
59. Efesoy O, Cayan S, Akbay E et al. The effect of alpha blocker therapy on sexual functions in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized prospective comparative study. J Sex Med 2009; 6 (suppl. 2): 45–193.
60. UA Practice Guideline Committee. AUA Guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530–47.
61. Kloner RA, Jackson G, Emmick JT et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935–40.
62. Giuliano F, Kaplan SA, Cabanis M-J, Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67 (6): 1199–204.
63. Lowe FC, McConnell JD, Hudson PB et al. Finasteride Study Group. Long-term 6-year experience with finasteride in patients with BPH. Urology 2003; 61: 791–6.
64. Wilton L, Pearce G, Edet E et al. The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14,722 patients BJU Int 1996; 78: 379–84.
65. Nickel JC, Fradet Y, Boake RC et al. Efficacy and safety of finasteride therapy for BPH: Results of a 2-year randomized controlled trial (the PROSPECT study). Can Med Assoc J 1994; 155: 1251–9.
66. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284–92.
67. McConnel JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med 2003; 349: 2387–98.